Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo Medical Center, 3120 Glendale Avenue, Mail Stop 1194, Toledo, OH 43614, United States.
Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):325-9. doi: 10.1016/j.ejogrb.2011.05.018. Epub 2011 Jul 28.
The objective of this pilot study was to determine if the combination of CA 125, menopausal status and prealbumin can be used to accurately predict ovarian cancer in women with pelvic masses.
Preoperative serum CA 125, prealbumin and menopausal status were prospectively determined. Results were formulated into an ovarian cancer risk assessment (OCRA) score and compared with final surgical pathology.
OCRA was studied in 130 women. No cancers were found in women with a score less than 200. For all cancers, an OCRA score ≥ 200 had a sensitivity of 96%, specificity of 95% and positive predictive value of 95%. When the OCRA score of ≥ 200 was evaluated for its ability to predict ovarian cancer, the sensitivity, specificity, and positive predictive value were 100%, 83%, and 78%, respectively.
In this pilot study, OCRA was able to predict which women with pelvic masses were more likely to have ovarian cancer. The scoring system easily applied clinically and may help facilitate appropriate referral of women to gynecologic oncologists for optimal care.
本初步研究旨在确定 CA125、绝经状态和前白蛋白的联合应用是否可用于准确预测盆腔肿块女性的卵巢癌。
前瞻性地确定术前血清 CA125、前白蛋白和绝经状态。将结果制定为卵巢癌风险评估 (OCRA) 评分，并与最终手术病理进行比较。
OCRA 研究共纳入 130 例女性。评分低于 200 的女性中未发现癌症。对于所有癌症，OCRA 评分≥200 的敏感性为 96%、特异性为 95%和阳性预测值为 95%。当评估 OCRA 评分≥200 预测卵巢癌的能力时，敏感性、特异性和阳性预测值分别为 100%、83%和 78%。
在本初步研究中，OCRA 能够预测哪些盆腔肿块女性更有可能患有卵巢癌。该评分系统易于临床应用，可能有助于促进将女性适当转诊给妇科肿瘤医生以获得最佳治疗。
